Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects

Bristol-Myers Squibb (BMS)

Status and phase

Completed

Phase 1

Conditions

Depression

Treatments

Drug: BMS-866949

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00949767

EUDRACT # is 2009-010220-26

CN166-001

Details and patient eligibility

About

The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects.

Enrollment

64 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy male 18-55
Women not of child bearing potential, 18-55

Exclusion criteria

History of or current treatment for psychiatric illnesses, substance abuse or dependence
History of a clinically significant neurological disorder (e.g., history of stroke, head trauma, etc.)

Trial design

64 participants in 7 patient groups

BMS-866949 (Panel 1)

Experimental group

Treatment:

Drug: Placebo

Drug: BMS-866949

BMS-866949 (Panel 2)

Experimental group

Treatment:

Drug: Placebo

Drug: BMS-866949

BMS-866949 (Panel 3)

Experimental group

Treatment:

Drug: Placebo

Drug: BMS-866949

BMS-866949 (Panel 4)

Experimental group

Treatment:

Drug: Placebo

Drug: BMS-866949

BMS-866949 (Panel 5)

Experimental group

Treatment:

Drug: Placebo

Drug: BMS-866949

BMS-866949 (Panel 6)

Experimental group

Treatment:

Drug: Placebo

Drug: BMS-866949

BMS-866949 (Panel 7)

Experimental group

Treatment:

Drug: Placebo

Drug: BMS-866949

Trial contacts and locations

1

Loading...